English Title:
Frazier Life Sciences Acquisition Corp. II Announces Pricing of $75,000,000 Initial Public Offering

中文标题：
Frazier生命科学收购公司 二公司宣布75,000,000美元的定价

English Content:
PALO ALTO, Calif., October 14, 2026--(BUSINESS WIRE)--Frazier Life Sciences Acquisition Corp. II (the "Company"), a special purpose acquisition company, announced today that it priced its initial public offering of 7,500,000 Class A ordinary shares at a price of $10.00 per share. The Class A ordinary shares will be listed on The Nasdaq Capital Market and trade under the ticker symbol "FLSC" beginning on October 14, 2026. The offering is expected to close on October 15, 2026, subject to customary closing conditions. The Company was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company is sponsored by Frazier Life Sciences Holdings II, LLC, an affiliate of Frazier Life Sciences Management, L.P., and is led by Chief Executive Officer Albert Cha, M.D., Ph.D., Chairman of the Board of Directors Ben Palleiko, and Chief Business Officer Kevin Li, M.D. While the Company may pursue an acquisition opportunity in any business, industry, sector or geographical location, it intends to capitalize on the experience and ability of its management team to identify promising opportunities in the biotechnology sector, with the goal of financing a company that can develop important new therapies for patients while creating value for shareholders. Jefferies is acting as the sole book-running manager for the offering. The offering is being made only by means of a prospectus. Copies of the prospectus may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at 877-821-7388 or by email at Prospectus_Department@Jefferies.com, or by accessing the Securities and Exchange Commission's (the "SEC") website, www.sec.gov. A registration statement relating to these securities has been declared effective by the SEC on October 13, 2026. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. CAUTIONARY NOTE CONCERNING FORWARD-LOOKING STATEMENTS This press release contains statements that constitute "forward-looking statements," including with respect to the expected closing of the proposed initial public offering and the Company's search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described above, or at all, or that, if completed, the proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement for the initial public offering filed with the SEC. Copies are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20261013289710/en/ Contacts Kevin Li, M.D. Chief Business Officer 1001 Page Mill Road, Building 4, Suite 200B Palo Alto, CA 93404 Tel.: (650) 325-5156 Email: KL@frazierls.com

中文正文：
PALO ALTO, Calif., 2026年10月14日-(BUSINess WIRE)-Frazier生命科学收购公司(简称"公司"),一家特殊目的收购公司,今天宣布其首次公开出价7,500,000A级普通股,每股价10.00美元. A级普通股将于2026年10月14日起在纳斯达克资本市场上市并进行交易,代号为"FLSC". 预计在2026年10月15日结束,但须遵守习惯性的关闭条件. 公司成立的目的是与一个或多个企业进行合并,合并,股份交易,资产收购,股份购买,重组或类似的业务组合. 公司由Frazier Life Science Holdings II,LLC,Frazier Life Science Management的子公司L.P.赞助,并由首席执行官阿尔伯特·查,博士,博士,董事长本·帕莱科,首席商务官凯文·李,M.D. 虽然该公司可能在任何企业、工业、部门或地理位置寻找收购机会,但它打算利用其管理团队的经验和能力,以便 查明生物技术部门有希望的机会,目标是资助一个公司,为病人开发重要的新疗法,同时为股东创造价值。 Jefferies正在担任 唯一的账务经理 供货。 献礼只能通过预告片进行. 可从纽约麦迪逊大道520号2层的Jefferies LLC处(注意:公平信条前景部,纽约,10022年,或电话877-821-7388,或Prospectus Department@Jefferies.com的电子邮件,或访问证券交易委员会网站(www.sec.gov)。 2026年10月13日,证监会宣布与这些证券有关的注册声明生效. 这份新闻稿不应构成出售要约或征求要约,也不应构成在任何国家或法域的证券法规定,在登记或取得资格之前,这种要约、邀约或出售均属非法的任何国家或法域出售这些证券。 关于准备发言的简要说明 本新闻稿载有: (b) 构成“前瞻性声明”的声明,包括预期终止拟议的初始公开报价和公司寻求初始业务组合的声明。 无法保证上文讨论的报价将按上述条件完成,或完全完成,或者,如果完成,报价的收益将按所示使用。 前瞻性声明受到许多条件的限制,其中许多条件超出了公司的控制范围,包括公司向证监会提交的初始公开报价登记声明的“风险因素”部分。 可在证交会网站www.sec.gov上查阅。 除法律要求外,公司没有义务在发布日期后更新这些报表以供修改或更改。 在businesswire.com上查看来源版本:https://www.businesswire.com/news/home/20261013289710/en/Contacts Kevin Li, M.D.首席商务官1001 Page Mill Road, Building 4, Suite 200B Palo Alto, CA 93404 电话:(650) 325-5156 电子邮件:KL@frazierls.com